Literature DB >> 31662450

SRSF2 Regulation of MDM2 Reveals Splicing as a Therapeutic Vulnerability of the p53 Pathway.

Daniel F Comiskey1,2,3, Matías Montes1,2,3, Safiya Khurshid1,2,3, Ravi K Singh1,2,3,4, Dawn S Chandler5,2,3.   

Abstract

MDM2 is an oncogene and critical negative regulator of tumor suppressor p53. Genotoxic stress causes alternative splicing of MDM2 transcripts, which leads to alterations in p53 activity and contributes to tumorigenesis. MDM2-ALT1 is one of the alternatively spliced transcripts predominantly produced in response to genotoxic stress, and is comprised of terminal coding exons 3 and 12. Previously, we found that SRSF1 induces MDM2-ALT1 by promoting MDM2 exon 11 skipping. Here we report that splicing regulator SRSF2 antagonizes the regulation of SRSF1 by facilitating the inclusion of exon 11 through binding at two conserved exonic splicing enhancers. Overexpression of SRSF2 reduced the generation of MDM2-ALT1 under genotoxic stress, whereas SRSF2 knockdown induced the expression of MDM2-ALT1 in the absence of genotoxic stress. Blocking the exon 11 SRSF2-binding sites using oligonucleotides promoted MDM2-ALT1 splicing and induced p53 protein expression, and apoptosis in p53 wild-type cells. The regulation of MDM2 splicing by SRSF2 is also conserved in mice, as mutation of one SRSF2-binding site in Mdm2 exon 11, using CRISPR-Cas9, increased the expression of the MDM2-ALT1 homolog Mdm2-MS2. IMPLICATIONS: Taken together, the data indicate that modulating MDM2 splicing may be a useful tool for fine-tuning p53 activity in response to genotoxic stress. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31662450     DOI: 10.1158/1541-7786.MCR-19-0541

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  6 in total

Review 1.  Targeting p53-MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials.

Authors:  Haohao Zhu; Hui Gao; Yingying Ji; Qin Zhou; Zhiqiang Du; Lin Tian; Ying Jiang; Kun Yao; Zhenhe Zhou
Journal:  J Hematol Oncol       Date:  2022-07-13       Impact factor: 23.168

Review 2.  Splicing factor SRSF2-centric gene regulation.

Authors:  Kun Li; Ziqiang Wang
Journal:  Int J Biol Sci       Date:  2021-04-16       Impact factor: 6.580

3.  Discovery and Validation of Serum Autoantibodies Against Tumor-Associated Antigens as Biomarkers in Gastric Adenocarcinoma Based on the Focused Protein Arrays.

Authors:  Qian Yang; Jiejie Qin; Guiying Sun; Cuipeng Qiu; Di Jiang; Hua Ye; Xiao Wang; Liping Dai; Jicun Zhu; Peng Wang; Jianying Zhang
Journal:  Clin Transl Gastroenterol       Date:  2020-12-21       Impact factor: 4.488

Review 4.  Therapeutic Targeting of Alternative RNA Splicing in Gastrointestinal Malignancies and Other Cancers.

Authors:  Ilyas Sahin; Andrew George; Attila A Seyhan
Journal:  Int J Mol Sci       Date:  2021-10-30       Impact factor: 5.923

5.  The effect of splicing MST1R in gastric cancer was enhanced by lncRNA FENDRR.

Authors:  Donghui Zhou; Xiaohua Zhu; Xuan Wu; Jingjing Zheng; Laizhen Tou; Yong Zhou
Journal:  Exp Ther Med       Date:  2021-05-25       Impact factor: 2.447

6.  Transcriptomic analyses of gastrulation-stage mouse embryos with differential susceptibility to alcohol.

Authors:  Karen E Boschen; Travis S Ptacek; Matthew E Berginski; Jeremy M Simon; Scott E Parnell
Journal:  Dis Model Mech       Date:  2021-06-17       Impact factor: 5.758

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.